Facial demodicosis in the immunosuppressed state: a retrospective case series from a tertiary referral center.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
18
01
2022
received:
24
09
2021
accepted:
04
03
2022
pubmed:
11
4
2022
medline:
15
9
2022
entrez:
10
4
2022
Statut:
ppublish
Résumé
Data on Demodex in the immunosuppressed state is limited, focusing mainly on patients with human immunodeficiency virus and hematological malignancies. The aim of this study was to describe the manifestations of facial demodicosis in diverse immunosuppressive states. The medical records of all patients followed at a Demodex outpatient clinic of a tertiary medical center from January 2008 to November 2020 were retrospectively reviewed. Data on patients who were immunosuppressed while with demodicosis were retrieved. The cohort included 28 patients (17 women and 11 men; median age, 58 years). Types of immunosuppression included treatments with hydroxyurea for polycythemia vera/essential thrombocytosis, mycophenolic acid, tacrolimus, and prednisone for liver and/or kidney transplantation, prednisone with cyclosporine/methotrexate/azathioprine/rituximab mainly for autoimmune diseases, mercaptopurine with/without anti-tumor necrosis factor alpha (TNF-α) for Crohn's disease, chemotherapy for neoplasms, anti-TNF-α for psoriasis, and Cushing's syndrome. The clinical types of demodicosis included: papulopustular, erythematotelangiectatic and fulminant rosacea, hyperpigmented, pityriasis folliculorum, pustular folliculitis, and dermatitis. The diverse clinical presentations led to various differential diagnoses. Topical treatment with ivermectin (monotherapy/combination with other treatments) was effective. Clinicians treating immunosuppressed patients should be familiar with the different forms of demodicosis and include them in the differential diagnosis of facial eruptions.
Sections du résumé
BACKGROUND
BACKGROUND
Data on Demodex in the immunosuppressed state is limited, focusing mainly on patients with human immunodeficiency virus and hematological malignancies. The aim of this study was to describe the manifestations of facial demodicosis in diverse immunosuppressive states.
METHODS
METHODS
The medical records of all patients followed at a Demodex outpatient clinic of a tertiary medical center from January 2008 to November 2020 were retrospectively reviewed. Data on patients who were immunosuppressed while with demodicosis were retrieved.
RESULTS
RESULTS
The cohort included 28 patients (17 women and 11 men; median age, 58 years). Types of immunosuppression included treatments with hydroxyurea for polycythemia vera/essential thrombocytosis, mycophenolic acid, tacrolimus, and prednisone for liver and/or kidney transplantation, prednisone with cyclosporine/methotrexate/azathioprine/rituximab mainly for autoimmune diseases, mercaptopurine with/without anti-tumor necrosis factor alpha (TNF-α) for Crohn's disease, chemotherapy for neoplasms, anti-TNF-α for psoriasis, and Cushing's syndrome. The clinical types of demodicosis included: papulopustular, erythematotelangiectatic and fulminant rosacea, hyperpigmented, pityriasis folliculorum, pustular folliculitis, and dermatitis. The diverse clinical presentations led to various differential diagnoses. Topical treatment with ivermectin (monotherapy/combination with other treatments) was effective.
CONCLUSION
CONCLUSIONS
Clinicians treating immunosuppressed patients should be familiar with the different forms of demodicosis and include them in the differential diagnosis of facial eruptions.
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1245-1252Informations de copyright
© 2022 the International Society of Dermatology.
Références
Rather PA, Hassan I. Human Demodex mite: The versatile mite of dermatological importance. Indian J Dermatol 2014; 59: 60-66.
Rufli T, Mumcuoglu Y. The hair follicle mites Demodex folliculorum and Demodex brevis: Biology and medical importance: a review. Dermatologica 1981; 162: 1-11.
Norn MS. Demodex folliculorum: incidence, regional distribution, pathogenicity. Dan Med Bull 1971; 18: 14-17.
Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case control study using standardized skin surface biopsy. Br J Dermatol 1993; 128: 650-659.
Forton F, Germaux MA, Brasseur T, et al. Demodicosis and rosacea: Epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol 2005; 52: 74-87.
Farina MC, Requena L, Sarasa JL, et al. Spinulosis of the face as a manifestation of demodicidosis. Br J Dermatol 1998; 138: 901-903.
Ayres S Jr. Pityriasis folliculorum (Demodex). Arch Derm Syphilol 1930; 21: 19-24.
Gold SC. Demodex dermatitis in a child. Br J Dermatol 1970; 83: 423.
Purcell SM, Hayes TJ, Dixon SL. Pustular folliculitis associated with Demodex folliculorum. J Am Acad Dermatol 1986; 15: 1159-1162.
Dominey A, Rozen T, Tschen J. Papulonodular demodicidosis associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 1989; 20: 197-201.
Grossmann B, Jung K, Linse R. Tuberös-pustulöse Demodikose [Tubero-pustular demodicosis]. Hautarzt. 1999;50:491-494. German 14.
Ayres S Jr, Ayres S 3rd. Demodectic eruptions (demodicidosis) in the human. 30 years' experience with 2 commonly unrecognized entities: pityriasis folliculorum (Demodex) and acne rosacea (Demodex type). Arch Dermatol 1961; 83: 816-827.
Forton F, De Maertelaer V. Erythematotelangiectatic rosacea may be associated with a subclinical stage of demodicosis: a case-control study. Br J Dermatol 2019; 181: 818-825.
Hsu CK, Hsu MM, Lee JY. Demodicosis: a clinicopathological study. J Am Acad Dermatol 2009; 60: 453-462.
Akçınar UG, Ünal E, Doğruman AF. Demodex spp. as a possible aetiopathogenic factor of acne and relation with acne severity and type. Postepy Dermatol Alergol 2018; 35: 174-181.
Karincaoglu Y, Tepe B, Kalayci B, et al. Is Demodex folliculorum an aetiological factor in seborrhoeic dermatitis? Clin Exp Dermatol 2009; 34: e516-e520.
Seyhan ME, Karincaoğlu Y, Bayram N, et al. Density of Demodex folliculorum in haematological malignancies. J Int Med Res 2004; 32: 411-415.
Keles H, Pancar Yuksel E, Aydin F, et al. Pre-treatment and post-treatment demodex densities in patients under immunosuppressive treatments. Medicina (Kaunas) 2020; 56: 107.
Kaya S, Selimoglu MA, Kaya OA, et al. Prevalence of Demodex folliculorum and Demodex brevis in childhood malnutrition and malignancy. Pediatr Int 2013; 55: 85-89.
Yagdiran Düzgün O, Aytekin S. Comparison of Demodex folliculorum density in haemodialysis patients with a control group. J Eur Acad Dermatol Venereol 2007; 21: 480-483.
Karincaoglu Y, Esrefoglu Seyhan M, Bayram N, et al. Incidence of Demodex folliculorum in patients with end stage chronic renal failure. Ren Fail 2005; 27: 495-499.
Jansen T, Kastner U, Kreuter A, et al. Rosacea-like demodicidosis associated with acquired immunodeficiency syndrome. Br J Dermatol 2001; 144: 139-142.
Sarro RA, Hong JJ, Elgart ML. An unusual demodicidosis manifestation in a patient with AIDS. J Am Acad Dermatol 1998; 38: 120-121.
Barrio J, Lecona M, Hernanz JM, et al. Rosacea-like demodicosis in an HIV-positive child. Dermatology 1996; 192: 143-145.
Ashack RJ, Frost ML, Norins AL. Papular pruritic eruption of Demodex folliculitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1989; 21: 306-307.
Redondo Mateo J, Soto Guzmán O, Fernández Rubio E, et al. Demodex-attributed rosacea-like lesions in AIDS. Acta Derm Venereol 1993; 73: 437.
Ivy SP, Mackall CL, Gore L, et al. Demodicidosis in childhood acute lymphoblastic leukemia; an opportunistic infection occurring with immunosuppression. J Pediatr 1995; 127: 751-754.
Sahn EE, Sheridan DM. Demodicidosis in a child with leukemia. J Am Acad Dermatol 1992; 27: 799-801.
Damian D, Rogers M. Demodex infestation in a child with leukaemia: Treatment with ivermectin and permethrin. Int J Dermatol 2003; 42: 724-726.
Herron MD, O’Reilly MA, Vanderhooft SL. Refractory Demodex folliculitis in five children with acute lymphoblastic leukemia. Pediatr Dermatol 2005; 22: 407-411.
Castanet J, Monpoux F, Mariani R, et al. Demodicidosis in an immunodeficient child. Pediatr Dermatol 1997; 14: 219-220.
Morrás PG, Santos SP, Imedio IL, et al. Rosacea-like demodicidosis in an immunocompromised child. Pediatr Dermatol 2003; 20: 28-30.
Román-Curto C, Meseguer-Yebra C, Cañueto J, et al. Demodicidosis simulating acute graft-versus-host disease after allogeneic stem cell transplantation in one patient with acute lymphoblastic leukemia. Transpl Infect Dis 2012; 14: 387-390.
Forton FMN, De Maertelaer V. Which factors influence Demodex proliferation? A retrospective pilot study ing a possible role of subtle immune variations and sebaceous gland status. J Dermatol 2021; 48: 1210-1220.
Segal R, Mimouni D, Feuerman H, et al. Dermoscopy as a diagnostic tool in demodicidosis. Int J Dermatol 2010; 49: 1018-1023.
De Amicis T. Demodex folliculorum e ipercromia cutanea. G Ital Malatta Venereo Pelle 1918; 33: 205-207.
Majocchi D. In discussion of De Amicis (1918). G Ital Malatta Venereol Pelle. 1918:33;205. ←De Amicis, Majoochi, and Dubreulh also cited in: http://www.doctortreatments.com/Diseases_Of_The_Skin/Class_IX_Parasitic_Affections_Diseases_Due_To_Animal_Parasites_Other_Animal_Parasites_Of_Minor_Importance_Penetrating_The_Skin.htm.
Dubreuilh W. Pigmentation cutanée causée par le demodex folliculorum. J Méd Bordeaux 1901; 31: 53.
Forton FM, Germaux MA, Thibaut SC, et al. Demodicosis: Descriptive classification and status of rosacea, in response to prior classification proposed. J Eur Acad Dermatol Venereol 2015; 29: 829-832.
Forton FMN, De Maertelaer V. Rosacea and demodicosis: Little-known diagnostic signs and symptoms. Acta Derm Venereol 2019; 99: 47-52.
Feuerman H, Atzmony L, Glick M, et al. Pigmented demodicidosis - an under-recognized cause of facial hyperpigmentation. Int J Dermatol 2021.
Falay Gur T, Erdemir AV, Gurel MS, et al. The investigation of the relationships of Demodex density with inflammatory response and oxidative stress in rosacea. Arch Dermatol Res 2018; 310: 759-767.
Ivermectin (Sklice lotion). Drugs.com. Sklice lotion. Date of approval: February 7, 2012. At: https://web.archive.org/web/20120512075611/http:/www.drugs.com/sklice.html.
Siddiqui K, Gold LS, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis. SpringerPlus 2016; 5: 1151.
Husein-ElAhmed H, Steinhoff M. Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: a systematic review and meta-analysis. Dermatol Ther 2020; 33(1): e13203.
Moran EM, Foley R, Powell FC. Demodex and rosacea revisited. Clin Dermatol 2017; 35: 195-200.
Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol 2017; 31: 1907-1911.